Novogen Limited (NVGN) Earns Daily Coverage Optimism Rating of 0.36
Media coverage about Novogen Limited (NASDAQ:NVGN) has trended positive on Saturday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novogen Limited earned a media sentiment score of 0.36 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 47.8603109447757 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Separately, ValuEngine cut Novogen Limited from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st.
Shares of Novogen Limited (NVGN) traded down 0.66% on Friday, hitting $3.00. The stock had a trading volume of 5,255 shares. The company’s 50 day moving average is $3.17 and its 200 day moving average is $1.66. The stock’s market cap is $14.50 million. Novogen Limited has a one year low of $0.70 and a one year high of $3.82.
TRADEMARK VIOLATION WARNING: “Novogen Limited (NVGN) Earns Daily Coverage Optimism Rating of 0.36” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/02/novogen-limited-nvgn-earns-daily-coverage-optimism-rating-of-0-36.html.
Novogen Limited Company Profile
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.
Receive News & Stock Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related stocks with our FREE daily email newsletter.